| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erectile Dysfunction | 12 | 2024 | 76 | 7.730 |
Why?
|
| Penile Implantation | 9 | 2024 | 14 | 6.580 |
Why?
|
| Penile Prosthesis | 10 | 2024 | 25 | 6.340 |
Why?
|
| Hypogonadism | 7 | 2024 | 40 | 4.020 |
Why?
|
| Penis | 10 | 2024 | 60 | 3.500 |
Why?
|
| Testosterone | 6 | 2024 | 276 | 2.530 |
Why?
|
| Penile Diseases | 4 | 2022 | 8 | 2.350 |
Why?
|
| Prostatic Hyperplasia | 4 | 2023 | 91 | 1.990 |
Why?
|
| Urologic Diseases | 3 | 2023 | 44 | 1.970 |
Why?
|
| Penile Induration | 3 | 2024 | 7 | 1.890 |
Why?
|
| Male | 77 | 2024 | 42632 | 1.770 |
Why?
|
| Infertility, Male | 3 | 2023 | 26 | 1.730 |
Why?
|
| Quality of Life | 7 | 2023 | 1676 | 1.370 |
Why?
|
| Humans | 88 | 2024 | 89760 | 1.320 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 714 | 1.270 |
Why?
|
| Hormone Replacement Therapy | 3 | 2024 | 85 | 1.260 |
Why?
|
| Prostatectomy | 8 | 2022 | 480 | 1.170 |
Why?
|
| Lower Urinary Tract Symptoms | 2 | 2021 | 69 | 1.160 |
Why?
|
| Organ Transplantation | 2 | 2021 | 279 | 1.140 |
Why?
|
| Urolithiasis | 2 | 2017 | 4 | 1.080 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2019 | 438 | 1.030 |
Why?
|
| Prostatic Neoplasms | 7 | 2021 | 1793 | 1.030 |
Why?
|
| Orchiectomy | 2 | 2024 | 72 | 1.020 |
Why?
|
| Kidney Neoplasms | 10 | 2019 | 639 | 1.020 |
Why?
|
| Nephrectomy | 12 | 2019 | 295 | 1.010 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2022 | 69 | 0.970 |
Why?
|
| Suture Techniques | 2 | 2024 | 144 | 0.950 |
Why?
|
| Testicular Neoplasms | 2 | 2024 | 113 | 0.950 |
Why?
|
| Cachexia | 1 | 2024 | 13 | 0.950 |
Why?
|
| Urinary Bladder | 3 | 2017 | 250 | 0.940 |
Why?
|
| Sperm Retrieval | 1 | 2024 | 3 | 0.930 |
Why?
|
| Fertility Preservation | 1 | 2024 | 19 | 0.900 |
Why?
|
| Semen | 1 | 2023 | 13 | 0.900 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 17 | 0.890 |
Why?
|
| Vasectomy | 1 | 2023 | 4 | 0.890 |
Why?
|
| Urinary Sphincter, Artificial | 2 | 2020 | 14 | 0.870 |
Why?
|
| Exosomes | 1 | 2023 | 53 | 0.860 |
Why?
|
| Postoperative Complications | 10 | 2024 | 2290 | 0.840 |
Why?
|
| Penile Erection | 4 | 2023 | 22 | 0.820 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 50 | 0.820 |
Why?
|
| Telemedicine | 2 | 2024 | 188 | 0.790 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.790 |
Why?
|
| Premature Ejaculation | 1 | 2021 | 1 | 0.780 |
Why?
|
| Genitalia | 1 | 2021 | 21 | 0.750 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2020 | 196 | 0.750 |
Why?
|
| Hyperthyroidism | 1 | 2021 | 75 | 0.750 |
Why?
|
| Mycophenolic Acid | 2 | 2011 | 84 | 0.740 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2020 | 406 | 0.740 |
Why?
|
| Transgender Persons | 1 | 2022 | 108 | 0.720 |
Why?
|
| Urinary Tract | 1 | 2021 | 35 | 0.720 |
Why?
|
| Extracorporeal Shockwave Therapy | 1 | 2020 | 2 | 0.720 |
Why?
|
| Vaping | 1 | 2021 | 45 | 0.710 |
Why?
|
| Urinary Incontinence | 1 | 2022 | 214 | 0.700 |
Why?
|
| Thrombosis | 2 | 2021 | 302 | 0.690 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2020 | 25 | 0.690 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 73 | 0.690 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 211 | 0.660 |
Why?
|
| Self-Injurious Behavior | 1 | 2021 | 111 | 0.630 |
Why?
|
| Retrospective Studies | 22 | 2022 | 9100 | 0.610 |
Why?
|
| Middle Aged | 30 | 2024 | 26129 | 0.600 |
Why?
|
| Treatment Outcome | 15 | 2024 | 8283 | 0.590 |
Why?
|
| Cystocele | 1 | 2016 | 7 | 0.570 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 977 | 0.550 |
Why?
|
| Kidney Transplantation | 3 | 2013 | 854 | 0.530 |
Why?
|
| Allografts | 1 | 2016 | 183 | 0.520 |
Why?
|
| Skin Transplantation | 1 | 2016 | 184 | 0.510 |
Why?
|
| Music Therapy | 1 | 2015 | 2 | 0.510 |
Why?
|
| Vagina | 1 | 2016 | 174 | 0.500 |
Why?
|
| Aged | 25 | 2023 | 19280 | 0.500 |
Why?
|
| Female | 32 | 2023 | 46439 | 0.500 |
Why?
|
| Health Care Costs | 1 | 2017 | 235 | 0.490 |
Why?
|
| Cystoscopy | 1 | 2015 | 39 | 0.490 |
Why?
|
| Edema | 1 | 2014 | 70 | 0.480 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 74 | 0.470 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 48 | 0.470 |
Why?
|
| Chronic Pain | 1 | 2016 | 162 | 0.460 |
Why?
|
| Kidney | 3 | 2019 | 1150 | 0.450 |
Why?
|
| Urology | 4 | 2020 | 120 | 0.450 |
Why?
|
| Drainage | 1 | 2014 | 165 | 0.450 |
Why?
|
| Prospective Studies | 6 | 2023 | 4328 | 0.440 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 329 | 0.440 |
Why?
|
| Adult | 20 | 2024 | 26742 | 0.440 |
Why?
|
| Fertility | 2 | 2023 | 116 | 0.430 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 32 | 0.420 |
Why?
|
| Anxiety | 1 | 2015 | 311 | 0.420 |
Why?
|
| Arthritis, Reactive | 1 | 2012 | 2 | 0.420 |
Why?
|
| Robotic Surgical Procedures | 4 | 2020 | 313 | 0.420 |
Why?
|
| Analgesics, Opioid | 2 | 2016 | 449 | 0.420 |
Why?
|
| Renal Veins | 2 | 2013 | 28 | 0.410 |
Why?
|
| Urography | 1 | 2012 | 45 | 0.410 |
Why?
|
| Obesity | 3 | 2020 | 972 | 0.410 |
Why?
|
| Pain | 1 | 2015 | 399 | 0.410 |
Why?
|
| BCG Vaccine | 1 | 2012 | 35 | 0.400 |
Why?
|
| Prevalence | 4 | 2021 | 1246 | 0.400 |
Why?
|
| Hematuria | 1 | 2012 | 50 | 0.400 |
Why?
|
| Guanine | 1 | 2013 | 207 | 0.400 |
Why?
|
| Osteolysis | 1 | 2011 | 14 | 0.400 |
Why?
|
| Nephrolithiasis | 1 | 2012 | 25 | 0.390 |
Why?
|
| Prosthesis Failure | 2 | 2024 | 116 | 0.390 |
Why?
|
| Femoral Neoplasms | 1 | 2011 | 23 | 0.390 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 73 | 0.390 |
Why?
|
| Lateral Ligament, Ankle | 1 | 2011 | 1 | 0.390 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 36 | 0.380 |
Why?
|
| Motor Activity | 1 | 2014 | 328 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 170 | 0.380 |
Why?
|
| Osteoblasts | 1 | 2011 | 98 | 0.380 |
Why?
|
| Laparoscopy | 5 | 2019 | 775 | 0.380 |
Why?
|
| Ankle | 1 | 2011 | 20 | 0.380 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 82 | 0.370 |
Why?
|
| Femur | 1 | 2011 | 112 | 0.370 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2012 | 175 | 0.360 |
Why?
|
| Azathioprine | 1 | 2011 | 124 | 0.360 |
Why?
|
| Diet | 1 | 2014 | 443 | 0.360 |
Why?
|
| Graft Survival | 2 | 2011 | 902 | 0.360 |
Why?
|
| HIV Infections | 3 | 2017 | 846 | 0.360 |
Why?
|
| Length of Stay | 6 | 2020 | 742 | 0.360 |
Why?
|
| Urinary Fistula | 1 | 2009 | 7 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 482 | 0.350 |
Why?
|
| Rectal Fistula | 1 | 2009 | 18 | 0.340 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 61 | 0.340 |
Why?
|
| Cadaver | 5 | 2012 | 186 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2013 | 480 | 0.330 |
Why?
|
| Urethra | 2 | 2020 | 115 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2665 | 0.320 |
Why?
|
| Androgen Antagonists | 3 | 2021 | 154 | 0.290 |
Why?
|
| Renal Artery | 1 | 2007 | 52 | 0.280 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 415 | 0.280 |
Why?
|
| Men's Health | 2 | 2024 | 6 | 0.280 |
Why?
|
| Ureteroscopy | 2 | 2017 | 38 | 0.270 |
Why?
|
| Lithotripsy | 2 | 2017 | 44 | 0.270 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2643 | 0.260 |
Why?
|
| Knee Joint | 1 | 2007 | 165 | 0.260 |
Why?
|
| United States | 5 | 2023 | 7037 | 0.260 |
Why?
|
| Cohort Studies | 6 | 2020 | 2882 | 0.260 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 260 | 0.260 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 3672 | 0.250 |
Why?
|
| Pain Measurement | 2 | 2016 | 331 | 0.230 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 39 | 0.230 |
Why?
|
| Seminoma | 1 | 2024 | 13 | 0.230 |
Why?
|
| Spermatogonia | 1 | 2023 | 13 | 0.230 |
Why?
|
| Adolescent | 6 | 2023 | 9295 | 0.230 |
Why?
|
| Cryopreservation | 1 | 2024 | 70 | 0.220 |
Why?
|
| Risk Factors | 8 | 2020 | 5522 | 0.220 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2023 | 15 | 0.220 |
Why?
|
| California | 2 | 2015 | 146 | 0.220 |
Why?
|
| Maternal Age | 1 | 2023 | 45 | 0.220 |
Why?
|
| Robotics | 2 | 2019 | 269 | 0.220 |
Why?
|
| Demography | 2 | 2015 | 183 | 0.220 |
Why?
|
| Gels | 1 | 2022 | 49 | 0.210 |
Why?
|
| Esthetics | 1 | 2022 | 45 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1078 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 1099 | 0.210 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 63 | 0.200 |
Why?
|
| Gender Identity | 1 | 2022 | 53 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 6847 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2023 | 163 | 0.200 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2012 | 41 | 0.200 |
Why?
|
| Syndrome | 1 | 2022 | 449 | 0.200 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 787 | 0.190 |
Why?
|
| North America | 2 | 2024 | 185 | 0.190 |
Why?
|
| Kidney Calculi | 2 | 2015 | 343 | 0.190 |
Why?
|
| Ejaculation | 1 | 2021 | 9 | 0.190 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2021 | 34 | 0.190 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 29 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 360 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 327 | 0.190 |
Why?
|
| Endoscopy | 2 | 2017 | 351 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2024 | 950 | 0.180 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 35 | 0.180 |
Why?
|
| Ireland | 2 | 2011 | 9 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2022 | 249 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2020 | 322 | 0.180 |
Why?
|
| Urethral Stricture | 1 | 2020 | 14 | 0.180 |
Why?
|
| Fibrosis | 1 | 2021 | 234 | 0.170 |
Why?
|
| Urinary Retention | 1 | 2020 | 42 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 21 | 0.170 |
Why?
|
| Dissection | 2 | 2011 | 44 | 0.170 |
Why?
|
| Medicare | 1 | 2023 | 426 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 460 | 0.170 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2020 | 14 | 0.170 |
Why?
|
| Abdominal Injuries | 1 | 2019 | 52 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1370 | 0.170 |
Why?
|
| Genitalia, Male | 1 | 2019 | 24 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2021 | 712 | 0.160 |
Why?
|
| Priapism | 1 | 2018 | 5 | 0.160 |
Why?
|
| Cannabis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Prosthesis Implantation | 1 | 2020 | 126 | 0.160 |
Why?
|
| Mortality | 1 | 2019 | 149 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 113 | 0.150 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 1218 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 88 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 201 | 0.150 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2017 | 8 | 0.150 |
Why?
|
| Specialization | 1 | 2017 | 66 | 0.140 |
Why?
|
| Operative Time | 4 | 2020 | 143 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2018 | 873 | 0.140 |
Why?
|
| Empyema | 1 | 2017 | 9 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 2025 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 329 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 100 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 374 | 0.140 |
Why?
|
| Australia | 1 | 2017 | 101 | 0.140 |
Why?
|
| Urinary Bladder Diseases | 1 | 2017 | 41 | 0.140 |
Why?
|
| Animals | 5 | 2023 | 27456 | 0.140 |
Why?
|
| Endocrinology | 1 | 2017 | 49 | 0.140 |
Why?
|
| Solvents | 1 | 2016 | 96 | 0.140 |
Why?
|
| Europe | 1 | 2017 | 322 | 0.130 |
Why?
|
| Ischemia | 1 | 2018 | 251 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 864 | 0.130 |
Why?
|
| Mice | 3 | 2023 | 11814 | 0.130 |
Why?
|
| Cryosurgery | 1 | 2016 | 54 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2016 | 2309 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 46 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 234 | 0.130 |
Why?
|
| Age Factors | 3 | 2016 | 1876 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 988 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 860 | 0.130 |
Why?
|
| Young Adult | 3 | 2023 | 6360 | 0.130 |
Why?
|
| Morbidity | 3 | 2020 | 149 | 0.120 |
Why?
|
| Graft Rejection | 2 | 2011 | 1072 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 145 | 0.120 |
Why?
|
| Bacteriuria | 1 | 2014 | 10 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 67 | 0.120 |
Why?
|
| Family Health | 1 | 2015 | 162 | 0.120 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2014 | 32 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 55 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 2015 | 45 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 160 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2014 | 35 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 51 | 0.120 |
Why?
|
| Logistic Models | 2 | 2015 | 1215 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2015 | 122 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 52 | 0.120 |
Why?
|
| Veterans | 1 | 2015 | 85 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2012 | 1226 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2017 | 352 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2014 | 12 | 0.110 |
Why?
|
| Fever | 1 | 2014 | 128 | 0.110 |
Why?
|
| Recurrence | 1 | 2017 | 1144 | 0.110 |
Why?
|
| Rats | 1 | 2020 | 4044 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 590 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 492 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 589 | 0.110 |
Why?
|
| Lamivudine | 1 | 2013 | 13 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 856 | 0.110 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 45 | 0.110 |
Why?
|
| Pelvis | 1 | 2013 | 96 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 42 | 0.100 |
Why?
|
| Medicaid | 1 | 2015 | 235 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 809 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 463 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 605 | 0.100 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2012 | 15 | 0.100 |
Why?
|
| Chloride Channels | 1 | 2012 | 42 | 0.100 |
Why?
|
| Pyrroles | 1 | 2013 | 187 | 0.100 |
Why?
|
| Rupture | 1 | 2011 | 61 | 0.100 |
Why?
|
| Cystostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 143 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 27 | 0.100 |
Why?
|
| Peritoneum | 1 | 2011 | 57 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 220 | 0.100 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 91 | 0.090 |
Why?
|
| Survival Rate | 2 | 2015 | 1910 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2013 | 187 | 0.090 |
Why?
|
| Mice, SCID | 1 | 2011 | 261 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 315 | 0.090 |
Why?
|
| Heart Atria | 1 | 2013 | 282 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2011 | 124 | 0.090 |
Why?
|
| Sepsis | 1 | 2014 | 322 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 580 | 0.090 |
Why?
|
| Urologic Surgical Procedures | 1 | 2012 | 147 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2011 | 47 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2013 | 298 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2011 | 237 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 253 | 0.090 |
Why?
|
| Child | 3 | 2011 | 7209 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2011 | 122 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2011 | 232 | 0.090 |
Why?
|
| Trauma Severity Indices | 2 | 2019 | 44 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2011 | 245 | 0.080 |
Why?
|
| Ependymoma | 1 | 2009 | 18 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 2579 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 3082 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2009 | 49 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 516 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2012 | 659 | 0.070 |
Why?
|
| Cystectomy | 2 | 2020 | 110 | 0.070 |
Why?
|
| Tendon Injuries | 1 | 2007 | 36 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2378 | 0.070 |
Why?
|
| Infant | 2 | 2011 | 3171 | 0.070 |
Why?
|
| Ligaments, Articular | 1 | 2007 | 38 | 0.070 |
Why?
|
| Menisci, Tibial | 1 | 2007 | 26 | 0.070 |
Why?
|
| Blood Transfusion | 2 | 2019 | 170 | 0.070 |
Why?
|
| Tendons | 1 | 2007 | 44 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2011 | 3752 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1451 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1281 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1848 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1601 | 0.060 |
Why?
|
| Wound Healing | 1 | 2007 | 360 | 0.060 |
Why?
|
| Hypospadias | 1 | 2024 | 7 | 0.060 |
Why?
|
| Blood Loss, Surgical | 2 | 2016 | 115 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2019 | 353 | 0.060 |
Why?
|
| Comorbidity | 2 | 2019 | 951 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1558 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 785 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2416 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2024 | 311 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3473 | 0.050 |
Why?
|
| Mutation | 1 | 2012 | 4167 | 0.040 |
Why?
|
| Pain, Postoperative | 2 | 2013 | 252 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2766 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 100 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 99 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 148 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 146 | 0.040 |
Why?
|
| Patient Simulation | 1 | 2018 | 42 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 185 | 0.040 |
Why?
|
| Anuria | 1 | 2017 | 6 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 256 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 61 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 603 | 0.030 |
Why?
|
| Urinary Diversion | 1 | 2017 | 42 | 0.030 |
Why?
|
| Coronary Thrombosis | 1 | 2016 | 14 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 25 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2018 | 231 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 310 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 774 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1535 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 455 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 160 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 308 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 199 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 148 | 0.030 |
Why?
|
| Anilides | 1 | 2014 | 48 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 102 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 395 | 0.030 |
Why?
|
| Nitriles | 1 | 2014 | 160 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 568 | 0.030 |
Why?
|
| Lymphocele | 1 | 2013 | 6 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 73 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 1185 | 0.030 |
Why?
|
| Anoctamins | 1 | 2012 | 1 | 0.030 |
Why?
|
| Finland | 1 | 2012 | 28 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2012 | 52 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 157 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2012 | 87 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1493 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 306 | 0.020 |
Why?
|
| Serenoa | 1 | 2011 | 1 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1721 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2012 | 62 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 148 | 0.020 |
Why?
|
| Abdomen | 1 | 2012 | 123 | 0.020 |
Why?
|
| Acidosis | 1 | 2011 | 55 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 790 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 309 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 313 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 503 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 99 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5346 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2012 | 221 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 887 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 795 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2011 | 136 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 786 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 961 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 684 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 550 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 127 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 469 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 607 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1599 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 3802 | 0.020 |
Why?
|
| World Health Organization | 1 | 2009 | 108 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 284 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2012 | 540 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2007 | 80 | 0.020 |
Why?
|
| Sutures | 1 | 2007 | 57 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 1852 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 327 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 432 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 600 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 1309 | 0.020 |
Why?
|
| Swine | 1 | 2007 | 587 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 2450 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2012 | 1380 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1802 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 1310 | 0.010 |
Why?
|